Wczytywanie kursów wyceny...
Prognoza
| Kupuj |
0 |
| Trzymaj |
1 |
| Sprzedaj |
0 |
Wiadomości Przejdź do aktualności
PainReform convenes annual general meeting on December 30 in Tel Aviv
PainReform announces that the annual general meeting will take place on December 30, 2025 at 3:00 p.m. Israel time in the offices of Amit, Pollak, Matalon & Co. in Tel Aviv. The company has distributed a notice of meeting and a proxy statement that describe the agenda items to be voted on and the voting procedures. Shareholders may attend in person or by proxy; a proxy form for written votes has been provided. Details on the agenda and voting procedures are included in the SEC filing. » Więcej na de.investing.com
PainReform cuts half-year loss sharply and expands biotech and solar projects
PainReform reports a net loss of $2.3m for H1 2025 versus $12.8m a year earlier, and shows $3.5m in cash and positive working capital. The company continues its dual strategy: acquisition of a majority stake in LayerBio including OcuRing-K and continuation of PRF-110 development, as well as completion of the MyDeepSolar app, entry into the NVIDIA Connect Program and a commercial agreement for a 92 MW pilot project in Romania. Despite operational progress, InvestingPro rates the financial situation 1.45/5 and flags high cash burn with negative EBITDA over the last twelve months. » Więcej na de.investing.com
Painreform shares fall after strategic investment in LayerBio
Painreform's stock dropped by 11% after the company announced a strategic investment in LayerBio. Painreform will acquire a majority stake in LayerBio and invest up to $3 million to expand its pipeline in non-opioid pain therapies. The investment aims to advance the development of the ophthalmic product OcuRing-K, while LayerBio will continue to operate independently. » Więcej na de.investing.com
Dane finansowe spółki
| (EUR) | grudzień 2025 | |
|---|---|---|
| Przychody | 14,49 tys. | - |
| Zysk brutto | -45,17 tys. | - |
| Zysk netto | -4,12 mln | - |
| EBITDA | -3,61 mln | - |
Dane fundamentalne
| Wskaźnik | Wartość |
|---|---|
Kapitalizacja rynkowa | 60,08 tys. € |
Liczba akcji | 80,53 tys. |
Maksimum/minimum z 52 tygodni | 6,89 € - 0,74 € |
| Dywidendy | Nie |
Beta | 1,04 |
C/Z (PE Ratio) | -0,02 |
PEG (PEG Ratio) | 0,00 |
C/WK (PB Ratio) | 0,07 |
C/S (PS Ratio) | 2,72 |
Profil spółki
PainReform Ltd. ist ein Spezialpharmaunternehmen in der klinischen Phase, das sich mit der Entwicklung von Therapeutika beschäftigt, die eine längere postoperative Schmerzlinderung in Israel ermöglichen. Das Unternehmen entwickelt PRF-110, eine viskose, klare Lösung auf Ölbasis, die direkt in die Operationswunde eingeträufelt wird, um eine lokalisierte und verlängerte postoperative Schmerzlinderung zu erzielen. Das Unternehmen führt derzeit zwei klinische Phase-3-Studien mit PRF-110 für die Behandlung von Patienten durch, die sich einer Bunionektomie und einer Hernienreparatur unterziehen. PainReform Ltd. wurde im Jahr 2007 gegründet und hat seinen Sitz in Tel Aviv, Israel.
| Nazwa | PAINREFORM LTD. IS-,01 Aktie |
| CEO | Efraim Cohen-Arazi |
| Siedziba | Tel Aviv,
ta Izrael |
| Strona internetowa | |
| Sektor | Materiały podstawowe |
| Branża | Chemikalia |
| Debiut giełdowy | 01.09.2020 |
| Pracownicy | 7 |
Symbole giełdowe
| Giełda | Symbol |
|---|---|
NASDAQ | PRFX |
